Table 1 Detailed summaries of the enrolled studies
From: The prevalence of people who inject drugs among those with HIV late presentation: a meta-analysis
Authors, year | Region | Type of study | The proportion of PWID with LP among all HIV-infected PWID (95% CI) | The proportion of PWID with LP to all HIV-infected patients (95% CI) | The odds of LP in PWID compared to MSMs (95% CI) | The odds of advanced disease in PWID compared to MSMs(95% CI) | Quality score | References |
|---|---|---|---|---|---|---|---|---|
Hu et al., 2019 | China | cross-sectional | 55 (52.4–58.4) | 1.89 (1.74–2.04) | 1.39 (1.2–1.67) | 2.06 (1.73–2.45) | 7* | [17] |
Wójcik-Cichy et al., 2018 | Poland | retrospective | 80 (67.57–89.77) | 17.37 (12.96–22.55) | 3.49 (1.63–7.48) |  | 8* | [18] |
Brannstrom et al., 2015 | Sweden | cohort | 42.8 (24.46–62.82) | 36.3 (18.9–62.5) | 1.11 (0.49–2.49) |  | 8* | [19] |
Wilton et al., 2018 | Canada | cohort | 47.65 (39.41–55.98) | 57.3 (45–71.7) | 0.94 (0.66–1.34) |  | 8* | [20] |
Camoni et al. 2013 | Italy | cohort | 59.76 (54.23–65.11) | 64.1 (55.7–73.3) | 1.86 (1.46–1.67) |  | 8* | [21] |
Siwak et al., 2019 | Poland | cross-sectional | 66.42 (62.69–70.00) | 19.87 (18.23–21.58) | 2.02 (1.68–2.42) | 2.68 (2.24–3.22) | 8* | [22] |
Sobrino-Vegas et al., 2012 | Spain | cohort | 26.64 (23.08–30.45) | 12.31 (10.54–14.26) | 0.72 (0.58–0.90) |  | 8* | [23] |
Op de Coul et al., 2014 | Netherlands | cohort | 78.77 (75.29–81.97) | 42.5 (38.8–46.4) | 2.53 (2.07–3.09) | 2.9 (2.35–3.58) | 8* | [24] |
Vives et al., 2012 | Spain | cohort | 55.7 (51.78–59.74) | 13.35 (12.06–14.71) | 1.66 (1.36–2.03) |  | 8* | [25] |
Metallidis et al., 2012 | Greece | retrospective | – | – | 2.19 (0.98–4.9) | 2.23 (1.02–4.86) | 8* | [26] |